Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Gel Manufacturing: SOP for Investigating Gel Batch Failures – V 2.0

Posted on By

Gel Manufacturing: SOP for Investigating Gel Batch Failures – V 2.0

Standard Operating Procedure for Investigation of Gel Batch Failures in Manufacturing


Department Gel Manufacturing
SOP No. SOP/GM/088/2025
Supersedes SOP/GM/088/2022
Page No. Page 1 of 14
Issue Date 02/06/2025
Effective Date 04/06/2025
Review Date 02/06/2026

1. Purpose

To define a systematic procedure for investigating failures or discrepancies observed in gel batches during manufacturing. This ensures identification of root causes, implementation of corrective and preventive actions (CAPA), and compliance with GMP and regulatory requirements.

2. Scope

This SOP applies to all gel batches that

exhibit deviations, out-of-specification (OOS) results, visual defects, microbial contamination, or other quality failures identified during any phase of manufacturing at the gel production facility.

3. Responsibilities

  • Production Department: Reporting of failures, initial documentation, and support in investigation.
  • Quality Assurance (QA): Leading investigations, conducting root cause analysis, CAPA implementation, and closure.
  • Quality Control (QC): Analytical testing, data review, and support in investigation.
  • Engineering Department: Equipment-related assessment and technical support.
See also  Gel Manufacturing: SOP for Labeling and Coding of Gel Products Before Secondary Packing - V 2.0

4. Accountability

Head – Quality Assurance shall be accountable for ensuring that all gel batch failures are properly investigated, documented, and closed with appropriate CAPA.

5. Procedure

5.1 Detection and Reporting

  1. Any production personnel identifying a potential failure (e.g., non-conforming appearance, consistency, pH, viscosity) shall immediately report to the production supervisor and QA.
  2. The concerned gel batch is labeled as “Under Investigation” and moved to quarantine storage.
  3. QA logs the incident in the Batch Failure Register (Annexure-1) and initiates an Investigation Report (Annexure-2).

5.2 Investigation Steps

  1. QA forms an Investigation Team consisting of representatives from Production, QA, QC, and Engineering.
  2. The team gathers the following data:
    • Batch Manufacturing Record (BMR)
    • Equipment cleaning logs
    • Environmental monitoring reports
    • Raw material COAs
    • In-process and final QC test results
  3. QA conducts interviews with operators, supervisors, and any personnel involved in the batch processing.
  4. Cross-checking of batch data with prior batches to identify recurrence patterns.

5.3 Root Cause Analysis (RCA)

  1. Use root cause tools like:
    • 5 Whys Analysis
    • Ishikawa (Fishbone) Diagram
    • Failure Mode and Effect Analysis (FMEA)
  2. All potential causes are evaluated to identify the most probable root cause(s).
See also  Gel Manufacturing: SOP for In-Process Viscosity Testing - V 2.0

5.4 Corrective and Preventive Actions (CAPA)

  1. Corrective actions are implemented to eliminate the immediate cause of failure.
  2. Preventive actions are proposed to prevent recurrence, which may include:
    • Process re-training
    • Procedure revisions
    • Equipment modification
    • Supplier qualification/review
  3. CAPA effectiveness is reviewed within 30 days post-implementation.

5.5 Disposition of the Batch

  1. Based on investigation outcome and QA decision, batch may be:
    • Rejected
    • Reprocessed (subject to regulatory approval)
    • Reworked
    • Released (if justified)

5.6 Documentation

  1. All investigation data is compiled in the Batch Failure Investigation Report (Annexure-2).
  2. QA Head signs off the investigation report and updates the Investigation Summary Log (Annexure-3).

6. Abbreviations

  • OOS: Out-of-Specification
  • CAPA: Corrective and Preventive Action
  • QA: Quality Assurance
  • QC: Quality Control
  • RCA: Root Cause Analysis

7. Documents

  1. Batch Failure Register – Annexure-1
  2. Batch Failure Investigation Report – Annexure-2
  3. Investigation Summary Log – Annexure-3
See also  Gel Manufacturing: SOP for Preparation of Water Phase for Gel Formulations - V 2.0

8. References

  • ICH Q10: Pharmaceutical Quality System
  • 21 CFR Part 211 – Subpart J: Records and Reports
  • WHO Technical Report Series 986 – Quality Risk Management

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation Jr. Production Chemist QA Executive Head – Manufacturing
Department Gel Manufacturing Quality Assurance Manufacturing

11. Annexures

Annexure-1: Batch Failure Register

Entry No. Date Batch No. Product Name Failure Type Reported By QA Reference

Annexure-2: Batch Failure Investigation Report

Report No.
Batch No.
Product
Failure Description
Date Identified
Root Cause Identified
Corrective Actions
Preventive Actions
Disposition Decision
Investigation Closed Date
QA Reviewer

Annexure-3: Investigation Summary Log

Sr. No. Batch No. Failure Type Date Opened Date Closed Disposition QA Remarks

Revision History

Revision Date Revision No. Change Description Reason Approved By
01/06/2022 1.0 Initial Issue New SOP QA Head
02/06/2025 2.0 Inclusion of annexures and RCA tools Periodic Review QA Head
Gels V 2.0 Tags:gel excipients SOP, gel extrudability SOP, gel formulation process guidelines, gel formulation safety SOP, gel formulation SOP template, gel homogenization SOP, gel ingredient weighing SOP, gel labeling and documentation SOP, gel microbial contamination SOP, gel packaging SOP, gel viscosity measurement SOP, gel viscosity testing SOP, pharmaceutical gel SOP, quality control SOP gel formulations, SOP for carbopol gel formulation, SOP for gel pH adjustment, SOP for gel spreadability test, stability testing SOP gel, standard operating procedure gel preparation, topical gel manufacturing SOP

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Sterility Testing of Injectable Products – V 2.0
Next Post: Elixir Department: SOP for Heating Using Steam Jacketed Systems – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version